Joe Rogan has discussed ibogaine on The Joe Rogan Experience across multiple episodes, in conversations about veteran PTSD, traumatic brain injury, and addiction that have reached tens of millions of listeners. The research he references is real. What those conversations rarely reach is the medical screening that determines whether any specific person is an appropriate candidate — and that question is the consequential one.
Ibogaine is an alkaloid from the root bark of Tabernanthe iboga. A single ceremony lasts 12–24 hours. The 2023 Stanford study found 88% reductions in PTSD symptoms, 87% in depression, and 81% in anxiety at one month in 30 special operations veterans. Ibogaine is Schedule I in the United States and has been since 1970. For North Americans, the nearest legal access is Vancouver, BC.
What Joe Rogan Has Said About Ibogaine
Rogan's coverage of ibogaine has centred on two themes: veteran mental health and addiction. His interest in both preceded the Stanford study — he has had researchers, veterans, and fighters on the podcast who discussed ibogaine in the context of PTSD, traumatic brain injury, and substance dependence they had not been able to resolve through conventional treatment.
The picture he has presented is largely accurate. Ibogaine produces significant reductions in PTSD severity and addiction in people who have not responded to conventional treatment. It is legal in Canada. The 2023 Stanford research, published in Nature Medicine, represents a genuine signal — not a fringe claim.
What podcast conversations do not cover is the specificity of candidacy. The cardiac screening. The medication conflicts. The question of whether the person listening right now — with their specific EKG findings, their SSRIs, their liver function — is someone for whom this medicine can be administered safely. That question cannot be answered by a podcast. It requires an intake process.
People who come expecting a certain kind of experience because they have heard about it on a podcast are, in Jake's experience, the group most likely to arrive unprepared. The medicine does not accommodate that gap. It delivers what the person needs, not what the podcast described — and those are often different things.
What the Research Actually Shows
The most-cited study is the 2023 Stanford paper published in Nature Medicine. The population was 30 special operations veterans with PTSD, traumatic brain injury, and treatment-resistant depression — people who had already gone through conventional treatment without adequate results.
At one month post-treatment:
- PTSD symptoms: 88% average reduction
- Depression symptoms: 87% average reduction
- Anxiety symptoms: 81% average reduction
Conventional antidepressant research considers a 50% reduction in depression scores a "strong response." The Stanford numbers are in a different category.
The study has real limitations. 30 veterans is not a definitive population. There was no placebo arm. These caveats are genuine — and the numbers are compelling enough to stand with them included, not in spite of omitting them. The $50 million committed to follow-up clinical trials at UTMB, UTHealth Houston, Texas A&M, and Baylor suggests institutional medicine has read the results the same way.
The full case for ibogaine research is available on the Research & Press page.
What Ibogaine Does — The Mechanism
Ibogaine acts on four receptor systems simultaneously. It is a partial agonist at mu-opioid receptors — which is why opioid withdrawal stops within hours rather than gradually. It inhibits the serotonin transporter and acts as an NMDA receptor antagonist. It appears to trigger release of GDNF — glial cell line-derived neurotrophic factor — a protein depleted in addiction-affected dopamine pathways.
This is what makes ibogaine distinct from every other addiction treatment: it addresses the neurological substrate of dependence rather than managing its symptoms. It is not a substitute opioid. It is not a craving suppressant. It is a neurological reset — a window during which craving is reduced and new patterns are more accessible than they would otherwise be. What happens in that window determines the long-term outcome. The medicine does not determine it alone.
More detail on the mechanism is in the post on what ibogaine does to the brain.
What Ibogaine Feels Like
The subjective accounts of ibogaine ceremony do not map onto other reference points cleanly. It is not dissociative in the way ketamine is. Not visually elaborate in the way psilocybin is. Not characterised by the panoramic quality of ayahuasca.
The content is biographical. In the early hours — typically the most intense — people review their own life in a format that is specific rather than symbolic. Not archetypal imagery. Actual memories, relationships, the pattern of decisions that led to where they are. The emotional charge that would normally accompany that review is reduced. People describe looking at painful material with something closer to clarity than to the distance of suppression.
The physical experience in the first hours typically includes tinnitus, closed-eye visuals, and ataxia — difficulty standing without support. Nausea is common. The experience is physically demanding in a way that surprises people regardless of what they have read beforehand.
The active experience runs 12–24 hours. What follows — the residual phase in which noribogaine, ibogaine's active metabolite, remains pharmacologically active for weeks — is where the integration work happens. The ceremony surfaces the material. The weeks after determine what is done with it. Providers who do not address this are not providing ibogaine treatment — they are providing ibogaine.
Details on each phase of the experience are in the post on the ibogaine experience.
Who Ibogaine Is Not For
This section matters more than the section above. The following are not cautions to weigh — they are conditions under which ibogaine cannot be administered safely.
Cardiac contraindications. QT prolongation on EKG, significant cardiac arrhythmia, or recent myocardial infarction. Ibogaine extends the QT interval for the duration of the active experience. This is the mechanism behind ibogaine-related deaths when the compound is administered without cardiac screening. A pre-ceremony 12-lead EKG identifies this contraindication. Skipping it does not make the risk disappear.
Current SSRIs or SNRIs.This is the most common contraindication in the population that wants ibogaine — because the most common conventional treatment for PTSD and depression is an SSRI, and many people who learn about ibogaine through Rogan's podcast are on one. Ibogaine inhibits the serotonin transporter. Combining it with serotonergic medications creates conditions for serotonin syndrome, which can be fatal. A completed, physician-supervised taper is required before ceremony. No exceptions.
Other medications and conditions. Lithium, methadone without a completed transition protocol, most antipsychotics, severe liver or kidney disease, active psychosis or schizophrenia-spectrum disorder, pregnancy.
Someone in acute psychiatric crisis is not an appropriate candidate, regardless of how urgently they want access. The experience amplifies what is present. Entering it in a state of acute destabilisation does not produce stabilisation.
The full contraindications list is in the post on ibogaine contraindications. The FAQ covers the most common screening questions.
Is This Right for You?
The starting point is not a booking. It is a medical screening conversation.
Every application to Transcend receives a personal response within 2–3 business days. No ceremony date is confirmed before screening establishes candidacy. The EKG, blood panel, medication review, and psychiatric history are not bureaucratic — they are the mechanism by which the most common and most dangerous contraindications are identified before ceremony, not during it.
For most people who heard about ibogaine through a podcast and are now researching whether it applies to their situation: the question is not whether the medicine is real. The research answers that. The question is whether you are an appropriate candidate, and whether the provider has the infrastructure to administer it safely.
Iboga ceremony at Transcend in Vancouver, BC costs $2,000–$5,000 CAD. This covers an on-site medical professional throughout the 12–24 hour active experience, continuous cardiac ECG monitoring, whole-plant root bark, facilitation, and a 2–3 day supervised recovery period. Integration coaching — $150–$300 CAD per session — is a separate service and is the part most directly responsible for whether the neuroplasticity window produces lasting change.
The ceremony page covers the full programme. The integration page covers what comes after. Or reach out directly to jake.nylund@gmail.com.